|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.450 USD | -1.43% |
|
-18.34% | -17.07% |
| 06-29 | Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark | CI |
| 06-29 | Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2500 Growth Benchmark | CI |
Company Valuation: Galectin Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 122.8 | 67.15 | 102.7 | 80.96 | 268.2 | 229.2 | - |
| Change | - | -45.33% | 52.89% | -21.14% | 231.27% | -14.55% | - |
| Enterprise Value (EV) | 122.8 | 67.15 | 102.7 | 80.96 | 268.2 | 229.2 | 229.2 |
| Change | - | -45.33% | 52.89% | -21.14% | 231.27% | -14.55% | 0% |
| P/E | -3.98x | -1.74x | -2.24x | -1.7x | -8.67x | -9.32x | -10.5x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0.1x | -0.2x | -0.63x | 0.2x | 0.4x | 1x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | -11.1x | -10x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -11.1x | -10x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.52 | -0.65 | -0.74 | -0.76 | -0.48 | -0.37 | -0.33 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | -20.7 | -22.9 |
| EBIT 1 | -30.18 | -38.35 | -38.07 | -42.43 | -20.08 | -20.7 | -22.9 |
| Net income 1 | -30.7 | -38.87 | -44.8 | -47.2 | -30.97 | -24.6 | -22.9 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 2.070 | 1.130 | 1.660 | 1.290 | 4.160 | 3.450 | 3.450 |
| Nbr of stocks (in thousands) | 59,341 | 59,426 | 61,849 | 62,762 | 64,473 | 65,857 | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/29/24 | 3/31/25 | 3/31/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.46x | - | - | - | 230M | |
| 31.99x | 5.69x | 17.6x | 1.03% | 46.06B | |
| -22.96x | 333.54x | -20.89x | -.--% | 38.91B | |
| 48.28x | 4.86x | 31.12x | -.--% | 35.57B | |
| 24.16x | 2.71x | 11.7x | -.--% | 33.13B | |
| 26.27x | 7.71x | 19.36x | 0.43% | 26.42B | |
| 31.03x | 5.02x | 22.85x | -.--% | 15.08B | |
| 24.17x | 2.07x | 9.1x | 1.09% | 14.08B | |
| 23.64x | 1.89x | 11.43x | -.--% | 12.81B | |
| Average | 19.68x | 45.44x | 12.78x | 0.32% | 24.7B | |
| Weighted average by Cap. | 22.05x | 62.31x | 11.81x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GALT Stock
- Valuation Galectin Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
